Sustained Response in a Phase 3 Study of Sarilumab Plus Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients with Active, Efficacy of Sarilumab in Combination with Csdmards in Patients with Rheumatoid Arthritis and Inadequate Response to TNF Inhibitors By Baseline Levels of Disease Activity